This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Artz AS, Pollyea DA, Kocherginsky M, Stock W, Rich E, Odenike O et al. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006; 12: 954–964.
Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912–2919.
Sorror ML, Storer B, Storb RF . Validation of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in single and multiple institutions: limitations and inferences. Biol Blood Marrow Transplant 2009; 15: 757–758.
Raimondi R, Tosetto A, Oneto R, Cavazzina R, Rodeghiero F, Bacigalupo A et al. Validation of the hematopoietic cell transplantation-specific comorbidity Index: a prospective, multicenter GITMO study. Blood 2012; 120: 1327–1333.
Le RQ, Bevans M, Savani BN, Mitchell SA, Stringaris K, Koklanaris E et al. Favorable outcomes in patients surviving 5 or more years after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2010; 16: 1162–1170.
Le RQ, Melenhorst JJ, Battiwalla M, Hill B, Memon S, Savani BN et al. Evolution of the donor T-cell repertoire in recipients in the second decade after allogeneic stem cell transplantation. Blood 2011; 117: 5250–5256.
Gratwohl A . The EBMT risk score. Bone Marrow Transplant 2012; 47: 749–756.
Lodewyck T, Oudshoorn M, van der Holt B, Petersen E, Spierings E . von dem Borne PA et al. Predictive impact of allele-matching and EBMT risk score for outcome after T-cell depleted unrelated donor transplantation in poor-risk acute leukemia and myelodysplasia. Leukemia 2011; 25: 1548–1554.
Porrata LF, Ristow K, Colgan JP, Habermann TM, Witzig TE, Inwards DJ et al. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma. Haematologica 2012; 97: 262–269.
Thoma MD, Huneke TJ, DeCook LJ, Johnson ND, Wiegand RA, Litzow MR et al. Peripheral blood lymphocyte and monocyte recovery and survival in acute leukemia postmyeloablative allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant 2012; 18: 600–607.
Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Hogan WJ et al. Day 100 peripheral blood absolute lymphocyte/monocyte ratio and survival in classical Hodgkin's lymphoma postautologous peripheral blood hematopoietic stem cell transplantation. Bone Marrow Res 2013; 2013: 658371.
Breiman L, Friedman JH, Olshen RA, Stone CJ . Classification and Regression Trees. Wadsworth International Group: : Belmont, CA, USA, 1984.
Pencina MJ, D’Agostino RB Sr, Steyerberg EW . Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011; 30: 11–21.
Acknowledgements
This work was supported by the Intramural Research Program of the NHLBI, NIH.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Le, R., Tian, X., Jain, N. et al. Clinical comorbidity predictive measures in ex vivo T-cell-depleted allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 50, 1138–1140 (2015). https://doi.org/10.1038/bmt.2015.112
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2015.112